<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20644" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Dobutamine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ashkar</surname>
            <given-names>Hamdallah</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Adnan</surname>
            <given-names>Ghufran</given-names>
          </name>
          <aff>Aga Khan University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Makaryus</surname>
            <given-names>Amgad N.</given-names>
          </name>
          <aff>Donald and Barbara Zucker School Medicine at Hofstra/Northwell</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hamdallah Ashkar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ghufran Adnan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amgad Makaryus declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>23</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20644.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Dobutamine is approved by the US Food and Drug Administration (FDA) for short-term use in patients with decreased contractility due to heart failure or cardiac procedures resulting in cardiac decompensation. Despite its ability to improve hemodynamics, dobutamine has not shown positive outcomes for heart failure patients in either the hospital or outpatient setting.</p>
        <p>In patients experiencing cardiogenic shock, short-term intravenous (IV) inotropic support with dobutamine is administered to sustain systemic blood flow and shield against end-organ damage. This off-label use of dobutamine serves as a transient measure until patients can undergo more definitive treatments such as coronary revascularization, mechanical circulatory support, or heart transplant.&#x000a0;This activity highlights the FDA-approved indications, off-label uses, mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of dobutamine pertinent to interprofessional healthcare team members involved in treating patients with cardiac disorders or aiming to attain hemodynamic stability.&#x000a0;</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate indications for dobutamine therapy in patients with decreased contractility due to heart failure or cardiac procedures.</p></list-item><list-item><p>Implement proper dosing protocols and infusion rate adjustments based on patient response and clinical status.</p></list-item><list-item><p>Select appropriate monitoring parameters to track the effectiveness and safety of dobutamine therapy&#x000a0;to optimize patient outcomes while minimizing risks.</p></list-item><list-item><p>Collaborate with the interprofessional healthcare teams to verify dosing, check for drug interactions, and address any concerns related to dobutamine administration, ensuring continuity and optimal outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20644&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20644">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20644.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Dobutamine is approved by the US Food and Drug Administration (FDA) for short-term use in patients with decreased contractility due to heart failure or cardiac procedures resulting in cardiac decompensation.<xref ref-type="bibr" rid="article-20644.r1">[1]</xref>&#x000a0;Despite dobutamine's ability to improve hemodynamic balance, the drug has not demonstrated positive outcomes for heart failure patients in either the hospital or outpatient setting.</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Dobutamine is used off-labeled as temporary intravenous (IV) inotropic support until the resolution of acute inducing factors or the patient receives more definitive treatment, such as coronary revascularization, mechanical circulatory support, or heart transplant. Short-term&#x000a0;IV inotropic support should be&#x000a0;provided for patients in cardiogenic shock to preserve systemic blood flow and protect them from end-organ damage. Patients can reasonably receive dobutamine in continuous&#x000a0;IV form for inotropic support to bridge patients with late-stage heart failure, stage D, refractory to guideline-directed medical therapy until patients who are candidates for and awaiting cardiac transplantation or mechanical circulatory support receive the appropriate long-term treatment.<xref ref-type="bibr" rid="article-20644.r2">[2]</xref></p>
        <p>Continuous&#x000a0;IV inotropic dobutamine support is used off-label. The medication can be given to hospitalized patients with severe systolic dysfunction who have low blood pressure and significantly reduced cardiac output to maintain systemic blood flow and protect against end-organ damage.&#x000a0;Long-term IV inotropic dobutamine support can be given to palliative patients with late-stage heart failure, stage D, who are not candidates for mechanical circulatory support or cardiac transplantation for symptomatic control, regardless of guideline-directed medical therapy.<xref ref-type="bibr" rid="article-20644.r3">[3]</xref>&#x000a0;IV inotropic dobutamine can be given off-label to patients to induce pharmacological stress during stress echocardiography (ECG) if patients cannot perform an exercise stress test.<xref ref-type="bibr" rid="article-20644.r4">[4]</xref><xref ref-type="bibr" rid="article-20644.r5">[5]</xref></p>
        <p>A retrospective study of positive inotropic agents for managing acute decompensated heart failure compared the safety and efficacy of dobutamine to milrinone. In the study, the median hospital length of stay, rehospitalization within 30 days, and median length of stay in the intensive care unit (ICU) were primary endpoints, and secondary endpoints were all-cause mortality, progression to renal failure within 72 hours, rehospitalization within 90 days, and urine output within 72 hours of therapy; all endpoints were not statistically significant.</p>
        <p>A post hoc analysis comparing primary and secondary outcomes between milrinone and dobutamine, accounting for baseline characteristics through linear and logistic regression, yielded no statistically significant findings. Overall, the study did not identify any significant differences in outcomes between the&#x000a0;2 treatment groups, except for a longer length of stay in the&#x000a0;ICU for the milrinone group.<xref ref-type="bibr" rid="article-20644.r6">[6]</xref></p>
      </sec>
      <sec id="article-20644.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Dobutamine is a pharmacological agent with ionotropic and chronotropic effects depending on the dose. Inotropic effects on the myocardium occur by selectively binding and activating the &#x003b2;-1 receptors.<xref ref-type="bibr" rid="article-20644.r7">[7]</xref> The medication is indicated for decompensated congestive heart failure because of the sympathomimetic effects. Dobutamine's ionotropic effect increases contractility, leading to decreased end-systolic volume and, therefore, increased stroke volume. The increase in stroke volume augments the heart's cardiac output (see <bold>Image.&#x000a0;</bold>Pressure-Volume Loop for Dobutamine).<xref ref-type="bibr" rid="article-20644.r8">[8]</xref></p>
        <p>The changes in cardiac output allow for the baroreceptor-mediated response to decrease systemic vascular resistance (SVR) and cause little to no change in arterial blood pressure. In addition to the well-known &#x003b2;-1 activity, dobutamine has some &#x003b2;-2 activity, which contributes to the reduction in SVR, and &#x003b1;-1 activity, to a lesser extent, whose vasoconstrictive effects are negated by the baroreceptor mediated response and &#x003b2;-2 activity.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>The majority of clinical studies with dobutamine have been limited to short-term duration, typically not exceeding several hours. In the limited cases where patients were monitored for 24, 48, and 72 hours,&#x000a0;researchers observed that some individuals exhibited a sustained elevation in cardiac output. In contrast, others experienced a return toward baseline levels.&#x000a0;Dobutamine typically has an onset of action&#x000a0;1 to&#x000a0;2 minutes after administration. However, achieving the maximum impact of an infusion rate may take up to&#x000a0;10 minutes. In humans, the plasma half-life of dobutamine is approximately&#x000a0;2 minutes. The primary processes involved in&#x000a0;the metabolism are catechol methylation and conjugation. The major excretion products found in human urine are the conjugates of dobutamine and 3-O-methyl dobutamine.</p>
      </sec>
      <sec id="article-20644.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>The medication&#x000a0;is available as dobutamine hydrochloride 1 mg/mL, 2 mg/mL, and 4 mg/mL in 250 ml and 250 mg/20 mL&#x000a0;IV solution.<bold>&#x000a0;</bold>Dobutamine administration is via extensive&#x000a0;IV access and infusion pump for inotropic support in decompensated congestive heart failure, stress echocardiogram, and stress nuclear testing.&#x000a0;Dobutamine&#x000a0;is available in a solution as a racemic mixture of both positive and negative enantiomers for&#x000a0;IV administration. The positive enantiomer in the solution is predominately selective for the &#x003b2;-sympathetic receptors, mainly &#x003b2;-1 and &#x003b2;-2. In contrast, the negative enantiomer&#x000a0;is selective for the &#x003b1;-1 receptors.<xref ref-type="bibr" rid="article-20644.r9">[9]</xref></p>
        <p>
<bold>Adult Dosages</bold>
</p>
        <p>Dobutamine&#x000a0;dosage for cardiac decompensation in heart&#x000a0;failure can begin with a low dose of 0.5 to 1.0 mcg/kg/min and increase to a maximum of 40 mcg/kg/min. The lower doses of&#x000a0;dobutamine can be prescribed at 2.5 to 5.0 mcg/kg/min, and the higher end of dobutamine doses can be 5.0 to 20.0&#x000a0;mcg/kg/min.<xref ref-type="bibr" rid="article-20644.r10">[10]</xref>&#x000a0;Before administration, parenteral drug products should be visually inspected for particulate matter and discoloration, as long as the solution and container allow for&#x000a0;the inspection.</p>
        <p>The infusion rate should then be adjusted at short intervals, considering the patient's response. Factors such as systemic blood pressure, frequency of ectopic activity, heart rate, urine flow, and, whenever possible, central venous pressure measurements, cardiac output, and/or pulmonary capillary wedge pressure should guide the titration process. Optimal infusion rates have varied between patients in reported trials, typically ranging from 2 to 20 mcg/kg/min, slightly below this range. In rare instances, infusion rates as high as 40 mcg/kg/min&#x000a0;are necessary to achieve the desired effect. The stress echocardiogram and stress nuclear test dose is initiated at 5 mcg/kg/min and can be increased in intervals of 10 mcg/kg/min every 3 to 5 minutes until the target heart rate is reached.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Research on administering&#x000a0;the drug to pregnant&#x000a0;patients has not been conducted, and it should be employed only when the anticipated benefits significantly outweigh the potential risks to the developing fetus.<xref ref-type="bibr" rid="article-20644.r11">[11]</xref></p>
        <p><bold>Pediatric considerations:</bold>&#x000a0;Dobutamine has demonstrated&#x000a0;the ability to enhance cardiac output and systemic pressure in pediatric patients across all ages. However, dopamine&#x000a0;is more effective in premature neonates than dobutamine in increasing systemic blood pressure without causing excessive tachycardia.&#x000a0;Evidence does not&#x000a0;suggest that dobutamine provides any additional advantages when administered to infants who are already receiving optimal dopamine infusions.</p>
        <p><bold>Older patients:</bold>&#x000a0;The clinical trials conducted on dobutamine did not involve an adequate number of participants aged 65 and older to establish whether they exhibit different responses compared&#x000a0;to younger individuals. However, observations from other clinical reports have not indicated any notable variations in the drug's effects between older adults and younger patients. As a general guideline, cautious dosing is recommended for patients 65 and older, typically starting at lower doses within the prescribed range. This approach considers the higher likelihood of reduced hepatic, renal, or cardiac function and the presence of concurrent illnesses or drug treatments.</p>
      </sec>
      <sec id="article-20644.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Dobutamine administration can lead to possible adverse reactions, mainly due to sympathomimetic activity.<xref ref-type="bibr" rid="article-20644.r12">[12]</xref>&#x000a0;Most patients taking this medication have experienced a rise in systolic blood pressure from 10 to 20 mm Hg&#x000a0;and an increase of 5 to 10 beats per minute (bpm) in their heart rate. Increased systolic blood pressure and heart rate have been reported. In about 10% of the patients, a rise of 30 bpm or more in the heart rate is expected, and&#x000a0;in about 7.5% of patients, a 50 mm Hg or more increase in the systolic blood pressure is expected. Patients with preexisting hypertension are more susceptible to the adverse effects on systolic blood pressure when using dobutamine.<xref ref-type="bibr" rid="article-20644.r13">[13]</xref><xref ref-type="bibr" rid="article-20644.r14">[14]</xref></p>
        <p>Dobutamine increases the risk of rapid ventricular response in patients with preexisting atrial fibrillation. The recommendation&#x000a0;for these patients is to use a regimen of digoxin before starting dobutamine to decrease the risk of developing atrial fibrillation with a rapid ventricular response.&#x000a0;An increased risk of developing premature ventricular beats is evident during the administration of dobutamine. About 5% of patients experience premature ventricular beats.<xref ref-type="bibr" rid="article-20644.r15">[15]</xref></p>
        <p>Other adverse effects caused by this medication include hypotension rarely. While increases in systolic blood pressure are common due to dobutamine, hypotension occurs less frequently due to decreased SVR. Recommendations include reducing the dose or discontinuing the drug to reverse the hypotensive effects.</p>
        <p>Phlebitis at the site of the&#x000a0;IV administration can occur but is an uncommon reaction.<xref ref-type="bibr" rid="article-20644.r16">[16]</xref> Dobutamine can rarely reduce potassium concentrations to hypokalemic levels. Other rare adverse effects have occurred in&#x000a0;1% to&#x000a0;3%&#x000a0;of the patients, including nausea, headaches, chest pain, palpitations, and shortness of breath. Dobutamine contains sulfite, which can lead to reactions in rare patients with sulfite hypersensitivity.<xref ref-type="bibr" rid="article-20644.r17">[17]</xref></p>
      </sec>
      <sec id="article-20644.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>According to the FDA, dobutamine use&#x000a0;is contraindicated in patients with a noted history of allergic reactions to either previous dobutamine use or any sulfite use. The medication is contraindicated in patients with hypokalemia, idiopathic hypertrophic sub-aortic stenosis, acute myocardial infarction, unstable angina, left main stem disease, severe hypertension, arrhythmias, acute myocarditis or pericarditis, and hypokalemia.</p>
        <p>
<bold>Box Warnings</bold>
</p>
        <p><bold>Increase in&#x000a0;heart rate or blood pressure:</bold> Dobutamine hydrochloride can significantly elevate heart rate and/or blood pressure, particularly systolic pressure. Clinical studies have shown that approximately 10% of adult patients experience a heart rate increase of 30 bpm or more. In comparison, about 7.5% have a systolic pressure increase of 50 mm Hg or greater. However, these effects&#x000a0;are reversible by reducing the dosage of the medication.</p>
        <p>As dobutamine enhances atrioventricular conduction, individuals with atrial fibrillation are at risk of developing a rapid ventricular response. To mitigate this risk,&#x000a0;the recommendation is to administer a digitalis preparation, such as digoxin, before initiating dobutamine therapy. Patients with preexisting hypertension also have a higher likelihood of experiencing an exaggerated pressure response. Therefore, careful blood pressure monitoring is essential to manage the condition effectively.</p>
        <p><bold>Ectopic activity:</bold> Dobutamine&#x000a0;can induce or exacerbate ventricular ectopic activity; incidents of dobutamine directly causing ventricular tachycardia are infrequent.</p>
        <p><bold>Hypersensitivity:</bold> Occasional reports have indicated hypersensitivity reactions associated with the administration of dobutamine in 5% dextrose injection, USP. These reactions may include skin rash, fever, eosinophilia, and bronchospasm. Dobutamine in 5% dextrose injection contains sodium bisulfite, a sulfite compound. Sulfites have the potential to cause allergic-type reactions, ranging from anaphylactic symptoms or severe allergic reactions to less severe episodes of asthma in susceptible individuals. The prevalence of sulfite sensitivity in the general population is uncertain but believed to be low. However, sulfite sensitivity is observed more frequently in individuals with asthma than those without asthma.</p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p><bold>General:&#x000a0;</bold>When administering dobutamine, continuously monitoring the patient's ECG and blood pressure is essential. This monitoring allows for close observation of any changes in heart rhythm and blood pressure response. Additionally, monitoring pulmonary wedge pressure and cardiac output can provide valuable information for ensuring the safe and effective dobutamine infusion. Hypovolemia should be assessed before initiating treatment with dobutamine.&#x000a0;</p>
        <p><bold>Administration following acute myocardial infarction:</bold>&#x000a0;Clinical knowledge regarding the use of dobutamine after myocardial infarction is limited, making it challenging to determine the drug's safety in this specific scenario.&#x000a0;Caution is necessary because any medication that enhances contractile force and heart rate might exacerbate ischemia, potentially leading to a&#x000a0;more significant infarction. However, it&#x000a0;is uncertain&#x000a0;if dobutamine has such an effect.</p>
        <p><bold>Drug interactions:</bold>&#x000a0;Dobutamine is contraindicated&#x000a0;for concomitant use with dihydroergotamine (synergistic effects) or phenelzine (additive effects). Both combinations can increase the risk of severe hypertension, including hypertensive crisis.</p>
        <p>Research suggests that when dobutamine and nitroprusside are coadministered, it generally leads to increased cardiac output and lower pulmonary wedge pressure&#x000a0;than when either drug is used individually. Combining dobutamine with catechol-O-methyltransferase (COMT) inhibitors&#x000a0;such as&#x000a0;entacapone may have potential effects such as an elevated heart rate, arrhythmias, and alterations in blood pressure.</p>
      </sec>
      <sec id="article-20644.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>With&#x000a0;the administration of dobutamine, continuous monitoring using a cardiac monitor and blood pressure checks are recommended because dobutamine is typically given to unstable patients and can lead to serious effects quickly that require monitoring and corrective action. The clinician can reduce the dose of dobutamine or stop the medication if the patient experiences adverse effects.</p>
      </sec>
      <sec id="article-20644.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Dobutamine toxicity is rare, and the half-life is short at 2 minutes. Symptoms are generally due to sympathetic overstimulation and can include chest pain, palpitations, headaches, tremors, shortness of breath, nausea, and vomiting. IV metoprolol can be given to reverse the tachycardia caused by dobutamine.</p>
      </sec>
      <sec id="article-20644.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Dobutamine is utilized in the ICU for managing low blood pressure, and although it is considered safe, dobutamine necessitates close monitoring due to its potential to elevate blood pressure and induce arrhythmias. Optimal therapeutic efficacy and avoidance of adverse effects are ensured through the engagement of an interprofessional healthcare team comprising ordering clinicians, specialists, nurses, and pharmacists. Nurses commonly oversee IV dobutamine administration and should, therefore, possess familiarity with dosing and monitoring parameters, alerting the ordering clinician to any observed patient concerns. Pharmacists, particularly those specializing in cardiology, verify dosing, check for drug interactions, and collaborate with other team members as necessary. The effects of dobutamine are transient, and the hemodynamic parameters reverse as soon as the infusion ceases. Effective treatment management with dobutamine for patients in scenarios involving decreased contractility due to heart failure or surgical procedures leading to decompensation relies on collaboration and open communication among all interprofessional team members to achieve optimal patient outcomes.</p>
      </sec>
      <sec id="article-20644.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20644&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20644">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20644/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20644">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-20644.s11">
        <fig id="article-20644.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Pressure-Volume Loop for Dobutamine. The pressure-volume loop for dobutamine compares a control to the ionotropic effects of this drug. Contributed by StatPearls</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Dobutamine" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-20644.s12">
        <title>References</title>
        <ref id="article-20644.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McNally</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Can we do better than dobutamine?</article-title>
            <source>Circ Res</source>
            <year>2013</year>
            <month>Aug</month>
            <day>02</day>
            <volume>113</volume>
            <issue>4</issue>
            <fpage>355</fpage>
            <page-range>355-7</page-range>
            <pub-id pub-id-type="pmid">23908327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20644.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
            </person-group>
            <article-title>Clinical use of inotropic therapy for heart failure: looking backward or forward? Part I: inotropic infusions during hospitalization.</article-title>
            <source>Circulation</source>
            <year>2003</year>
            <month>Jul</month>
            <day>22</day>
            <volume>108</volume>
            <issue>3</issue>
            <fpage>367</fpage>
            <page-range>367-72</page-range>
            <pub-id pub-id-type="pmid">12876135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20644.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martens</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vercammen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ceyssens</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Luwel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Van Aerde</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Potargent</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Renaers</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dupont</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mullens</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Effects of intravenous home dobutamine in palliative end-stage heart failure on quality of life, heart failure hospitalization, and cost expenditure.</article-title>
            <source>ESC Heart Fail</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>562</fpage>
            <page-range>562-569</page-range>
            <pub-id pub-id-type="pmid">29341466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20644.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Currie</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology, Part 4: Nuclear Cardiology.</article-title>
            <source>J Nucl Med Technol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>97</fpage>
            <page-range>97-110</page-range>
            <pub-id pub-id-type="pmid">30770476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20644.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lattanzi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Picano</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Adamo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Varga</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Dobutamine stress echocardiography: safety in diagnosing coronary artery disease.</article-title>
            <source>Drug Saf</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>251</fpage>
            <page-range>251-62</page-range>
            <pub-id pub-id-type="pmid">10789822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20644.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelly</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Malloy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lupi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Positive Inotropic Agents in the Management of Acute Decompensated Heart Failure.</article-title>
            <source>J Cardiovasc Pharmacol</source>
            <year>2020</year>
            <month>May</month>
            <volume>75</volume>
            <issue>5</issue>
            <fpage>455</fpage>
            <page-range>455-459</page-range>
            <pub-id pub-id-type="pmid">32091426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20644.r7">
          <label>7</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Alhayek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Preuss</surname>
                <given-names>CV</given-names>
              </name>
            </person-group>
            <chapter-title>Beta 1 Receptors</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>14</day>
            <pub-id pub-id-type="pmid">30422499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20644.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kislitsina</surname>
                <given-names>ON</given-names>
              </name>
              <name>
                <surname>Rich</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Churyla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vorovich</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Ghafourian</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Shock - Classification and Pathophysiological Principles of Therapeutics.</article-title>
            <source>Curr Cardiol Rev</source>
            <year>2019</year>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>102</fpage>
            <page-range>102-113</page-range>
            <pub-id pub-id-type="pmid">30543176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20644.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruffolo</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>The pharmacology of dobutamine.</article-title>
            <source>Am J Med Sci</source>
            <year>1987</year>
            <month>Oct</month>
            <volume>294</volume>
            <issue>4</issue>
            <fpage>244</fpage>
            <page-range>244-8</page-range>
            <pub-id pub-id-type="pmid">3310640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20644.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erlemeier</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Kupper</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bleifeld</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Intermittent infusion of dobutamine in the therapy of severe congestive heart failure--long-term effects and lack of tolerance.</article-title>
            <source>Cardiovasc Drugs Ther</source>
            <year>1992</year>
            <month>Aug</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>391</fpage>
            <page-range>391-8</page-range>
            <pub-id pub-id-type="pmid">1520649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20644.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeejeebhoy</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Zelop</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Lipman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carvalho</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Joglar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mhyre</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Lapinsky</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Einav</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Warnes</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Page</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dainty</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Arafeh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Windrim</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Callaway</surname>
                <given-names>CW</given-names>
              </name>
              <collab>American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology</collab>
            </person-group>
            <article-title>Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association.</article-title>
            <source>Circulation</source>
            <year>2015</year>
            <month>Nov</month>
            <day>03</day>
            <volume>132</volume>
            <issue>18</issue>
            <fpage>1747</fpage>
            <page-range>1747-73</page-range>
            <pub-id pub-id-type="pmid">26443610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20644.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Russell</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Vasopressor therapy in critically ill patients with shock.</article-title>
            <source>Intensive Care Med</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>45</volume>
            <issue>11</issue>
            <fpage>1503</fpage>
            <page-range>1503-1517</page-range>
            <pub-id pub-id-type="pmid">31646370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20644.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mertes</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sawada</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Segar</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Foltz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Feigenbaum</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Symptoms, adverse effects, and complications associated with dobutamine stress echocardiography. Experience in 1118 patients.</article-title>
            <source>Circulation</source>
            <year>1993</year>
            <month>Jul</month>
            <volume>88</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-9</page-range>
            <pub-id pub-id-type="pmid">8319327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20644.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Aberle</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Altshuler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Piper</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Papadopoulos</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Comparative Effectiveness and Safety Between Milrinone or Dobutamine as Initial Inotrope Therapy in Cardiogenic Shock.</article-title>
            <source>J Cardiovasc Pharmacol Ther</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>130</fpage>
            <page-range>130-138</page-range>
            <pub-id pub-id-type="pmid">30175599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20644.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>David</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zaks</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Arrhythmias associated with intermittent outpatient dobutamine infusion.</article-title>
            <source>Angiology</source>
            <year>1986</year>
            <month>Feb</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>86</fpage>
            <page-range>86-91</page-range>
            <pub-id pub-id-type="pmid">3954157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20644.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silva</surname>
                <given-names>EVC</given-names>
              </name>
              <name>
                <surname>Ochiai</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Vieira</surname>
                <given-names>KRN</given-names>
              </name>
              <name>
                <surname>Pereira Barretto</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>The use of peripherally inserted central catheter reduced the incidence of phlebitis in heart failure patients: A randomized trial.</article-title>
            <source>J Vasc Access</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>942</fpage>
            <page-range>942-947</page-range>
            <pub-id pub-id-type="pmid">34812074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20644.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kang</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Koo</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Hypereosinophilia with rash to dobutamine infusion; sulfite hypersensitivity diagnosed by in&#x000a0;vitro stimulation assays.</article-title>
            <source>Allergol Int</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>65</volume>
            <issue>4</issue>
            <fpage>477</fpage>
            <page-range>477-480</page-range>
            <pub-id pub-id-type="pmid">27137991</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
